| [1] |
LI J, CAO F, YIN HL, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88. DOI: 10.1038/s41419-020-2298-2. |
| [2] |
ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312. |
| [3] |
TSURUSAKI S, TSUCHIYA Y, KOUMURA T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis, 2019, 10(6): 449. DOI: 10.1038/s41419-019-1678-y. |
| [4] |
EZQUERRO S, MOCHA F, FRÜHBECK G, et al. Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD[J]. J Clin Endocrinol Metab, 2019, 104(1): 21-37. DOI: 10.1210/jc.2018-01171. |
| [5] |
GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041. |
| [6] |
AFONSO MB, RODRIGUES PM, MATEUS-PINHEIRO M, et al. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease[J]. Gut, 2021, 70(12): 2359-2372. DOI: 10.1136/gutjnl-2020-321767. |
| [7] |
LEE DH, PARK JS, LEE YS, et al. SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity[J]. Autophagy, 2020, 16(11): 1949-1973. DOI: 10.1080/15548627.2020.1712108. |
| [8] |
LI Y, ZENG X, LU D, et al. Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis[J]. Hum Reprod, 2021, 36(4): 951-964. DOI: 10.1093/humrep/deaa363. |
| [9] |
KWON MY, PARK E, LEE SJ, et al. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death[J]. Oncotarget, 2015, 6(27): 24393-24403. DOI: 10.18632/oncotarget.5162. |
| [10] |
DONG H, QIANG Z, CHAI D, et al. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1[J]. Aging (Albany NY), 2020, 12(13): 12943-12959. DOI: 10.18632/aging.103378. |
| [11] |
GHANIM BY, QINNA NA. Nrf2/ARE axis signalling in hepatocyte cellular death[J]. Mol Biol Rep, 2022, 49(5): 4039-4053. DOI: 10.1007/s11033-022-07125-6. |
| [12] |
VALENTI L, MOSCATIELLO S, VANNI E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling-a propensity score-adjusted observational study[J]. QJM, 2011, 104(2): 141-149. DOI: 10.1093/qjmed/hcq170. |
| [13] |
YANG WS, KIM KJ, GASCHLER MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis[J]. Proc Natl Acad Sci U S A, 2016, 113(34): E4966- E4975. DOI: 10.1073/pnas.1603244113. |
| [14] |
DOLL S, PRONETH B, TYURINA YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13(1): 91-98. DOI: 10.1038/nchembio.2239. |
| [15] |
XIANG H, SHAO M, LU Y, et al. Kaempferol alleviates steatosis and inflammation during early non-alcoholic steatohepatitis associated with liver X receptor α-lysophosphatidylcholine acyltransferase 3 signaling pathway[J]. Front Pharmacol, 2021, 12: 690736. DOI: 10.3389/fphar.2021.690736. |
| [16] |
JIANG L, KON N, LI T, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545): 57-62. DOI: 10.1038/nature14344. |
| [17] |
CARLSON BA, TOBE R, YEFREMOVA E, et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration[J]. Redox Biol, 2016, 9: 22-31. DOI: 10.1016/j.redox.2016.05.003. |
| [18] |
WANG X, MA B, WEN X, et al. Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis[J]. Cell Death Discov, 2022, 8(1): 234. DOI: 10.1038/s41420-022-01011-7. |
| [19] |
DOLL S, FREITAS FP, SHAH R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575(7784): 693-698. DOI: 10.1038/s41586-019-1707-0. |
| [20] |
BERSUKER K, HENDRICKS JM, LI Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692. DOI: 10.1038/s41586-019-1705-2. |
| [21] |
LI L, NG SR, COLÓN CI, et al. Identification of DHODH as a therapeutic target in small cell lung cancer[J]. Sci Transl Med, 2019, 11(517): eaaw7852. DOI: 10.1126/scitranslmed.aaw7852. |
| [22] |
MAO C, LIU X, ZHANG Y, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer[J]. Nature, 2021, 593(7860): 586-590. DOI: 10.1038/s41586-021-03539-7. |
| [23] |
MAO X, HUANG D, RAO C, et al. Enoyl coenzyme A hydratase 1 combats obesity and related metabolic disorders by promoting adipose tissue browning[J]. Am J Physiol Endocrinol Metab, 2020, 318(3): E318-E329. DOI: 10.1152/ajpendo.00424.2019. |
| [24] |
LIU B, YI W, MAO X, et al. Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis[J]. Am J Physiol Endocrinol Metab, 2021, 320(5): E925-E937. DOI: 10.1152/ajpendo.00614.2020. |
| [25] |
SCHAUER PR, NOR HANIPAH Z, RUBINO F. Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world's leading diabetes organizations[J]. Cleve Clin J Med, 2017, 84(7 Suppl 1): S47-S56. DOI: 10.3949/ccjm.84.s1.06. |
| [26] |
YOUNOSSI ZM, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. DOI: 10.1016/S0140-6736(19)33041-7. |
| [27] |
CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367. |
| [28] |
IMAI H, MATSUOKA M, KUMAGAI T, et al. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis[J]. Curr Top Microbiol Immunol, 2017, 403: 143-170. DOI: 10.1007/82_2016_508. |
| [29] |
BELL LN, WANG J, MURALIDHARAN S, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondi abetic patients with nonalcoholic steatohepatitis trial follow-up study[J]. Hepatology, 2012, 56(4): 1311-1318. DOI: 10.1002/hep.25805. |
| [30] |
LAVINE JE, SCHWIMMER JB, van NATTA ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial[J]. JAMA, 2011, 305(16): 1659-1668. DOI: 10.1001/jama.2011.520. |
| [31] |
KLEIN EA, THOMPSON IM Jr, TANGEN CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)[J]. JAMA, 2011, 306(14): 1549-1556. DOI: 10.1001/jama.2011.1437. |
| [32] |
SCHÜRKS M, GLYNN RJ, RIST PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials[J]. BMJ, 2010, 341: c5702. DOI: 10.1136/bmj.c5702. |
| [33] |
KUNG YA, CHIANG HJ, LI ML, et al. Acyl-coenzyme a synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis[J]. mBio, 2022, 13(1): e0271721. DOI: 10.1128/mbio.02717-21. |
| [34] |
CUSI K, ORSAK B, BRIL F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial[J]. Ann Intern Med, 2016, 165(5): 305-315. DOI: 10.7326/M15-1774. |
| [35] |
AUBERT RE, HERRERA V, CHEN W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes[J]. Diabetes Obes Metab, 2010, 12(8): 716-721. DOI: 10.1111/j.1463-1326.2010.01225.x. |
| [36] |
TANG H, SHI W, FU S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis[J]. Cancer Med, 2018, 7(4): 1070-1080. DOI: 10.1002/cam4.1354. |
| [37] |
AVCI B, GÜNAYDIN C, GÜVENÇ T, et al. Idebenone ameliorates rotenone-induced parkinson's disease in rats through decreasing lipid peroxidation[J]. Neurochem Res, 2021, 46(3): 513-522. DOI: 10.1007/s11064-020-03186-w. |
| [38] |
JIANG JX, TOMILOV A, MONTGOMERY C, et al. Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice[J]. J Biochem Mol Toxicol, 2021, 35(10): e22876. DOI: 10.1002/jbt.22876. |
| [39] |
TOMILOV A, ALLEN S, HUI CK, et al. Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition[J]. Pharmacol Res, 2018, 137: 89-103. DOI: 10.1016/j.phrs.2018.09.024. |
| [40] |
YAN N, XU Z, QU C, et al. Dimethyl fumarate improves cognitive deficits in chronic cerebral hypoperfusion rats by alleviating inflammation, oxidative stress, and ferroptosis via NRF2/ARE/NF-κB signal pathway[J]. Int Immunopharmacol, 2021, 98: 107844. DOI: 10.1016/j.intimp.2021.107844. |
| [41] |
VANANI AR, KALANTARI H, MAHDAVINIA M, et al. Dimethyl fumarate reduces oxidative stress, inflammation and fat deposition by modulation of Nrf2, SREBP-1c and NF-κB signaling in HFD fed mice[J]. Life Sci, 2021, 283: 119852. DOI: 10.1016/j.lfs.2021.119852. |
| [42] |
QIU YB, WAN BB, LIU G, et al. Nrf2 protects against seawater drowning-induced acute lung injury via inhibiting ferroptosis[J]. Respir Res, 2020, 21(1): 232. DOI: 10.1186/s12931-020-01500-2. |
| [43] |
ZHU Z, ZHANG Y, HUANG X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4[J]. Eur J Pharmacol, 2021, 908: 174351. DOI: 10.1016/j.ejphar.2021.174351. |
| [44] |
KONTOGHIORGHE CN, KONTOGHIORGHES GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes[J]. Drug Des Devel Ther, 2016, 10: 465-481. DOI: 10.2147/DDDT.S79458. |
| [45] |
WU S, YANG J, SUN G, et al. Macrophage extracellular traps aggravate iron overload-related liver ischaemia/reperfusion injury[J]. Br J Pharmacol, 2021, 178(18): 3783-3796. DOI: 10.1111/bph.15518. |
| [46] |
LUO Y, CHEN H, LIU H, et al. Protective effects of ferroptosis inhibition on high fat diet-induced liver and renal injury in mice[J]. Int J Clin Exp Pathol, 2020, 13(8): 2041-2049.
|
| [47] |
QI J, KIM JW, ZHOU Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice[J]. Am J Pathol, 2020, 190(1): 68-81. DOI: 10.1016/j.ajpath.2019.09.011. |
| [48] |
YANG Y, CHEN J, GAO Q, et al. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease[J]. Toxicology, 2020, 445: 152599. DOI: 10.1016/j.tox.2020.152599. |
| [49] |
GAO G, XIE Z, LI EW, et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis[J]. J Nat Med, 2021, 75(3): 540-552. DOI: 10.1007/s11418-021-01491-4. |
| [50] |
JIANG JJ, ZHANG GF, ZHENG JY, et al. Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity[J]. Front Pharmacol, 2022, 13: 876550. DOI: 10.3389/fphar.2022.876550. |
DownLoad: